Epidyolex

Epidyolex, the first FDA approved CBD medicine for severe epilepsy in children, received Australian Therapeutic Goods Administration approval. GW Pharmaceuticals plc (NASDAQ: GWPH) confirmed Wednesday that TGA authorized the medicine to treat Lennox-Gastaut syndrome (LGS) or Dravet...

GW Pharmaceuticals plc (NASDAQ: GWPH) said Friday it has submitted a Type II Variation Application to the European Medicines Agency, applying for authorization of its Epidyolex — Epidiolex in the U.S. — cannabidiol oral solution for the management of seizures related to tuberous...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced Sunday that two of its medicines have been recommended by the U.K.’s National Institute for Health and Care Excellence to receive routine reimbursement from the National Health Service.  What Happened Epidiolex, known as...